Multicenter, Open-label Trial, Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Patients With Partial Onset Seizures With or Without Secondary Generalized Seizures

Trial Profile

Multicenter, Open-label Trial, Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Patients With Partial Onset Seizures With or Without Secondary Generalized Seizures

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 May 2017

At a glance

  • Drugs Perampanel (Primary)
  • Indications Epilepsy; Generalised seizures; Partial epilepsies
  • Focus Therapeutic Use
  • Sponsors Eisai Korea
  • Most Recent Events

    • 24 May 2017 Planned End Date changed from 1 Jan 2018 to 1 May 2018.
    • 24 May 2017 Planned primary completion date changed from 1 Jan 2018 to 1 May 2018.
    • 12 May 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top